AbbVie Inc. stock gains on Apogee deal and reaffirmed 2026 guidance

AbbVie Inc. stock is holding near its highs as the drugmaker closes the USD 10.9 billion Apogee acquisition and reaffirms strong 2026 earnings guidance, while investors watch how new immunology blockbusters Skyrizi and Rinvoq offset shrinking Humira revenue.

AbbVie Inc. (ISIN US00287Y1091) stock is trading around USD 260 as of September 4, 2026, after the company completed its USD 10.9 billion acquisition of Apogee Therapeutics and reaffirmed robust full-year 2026 earnings guidance in the range of USD 13.87 to USD 14.07 per share.

Apogee acquisition strengthens immunology pipeline

According to a report on Allsci dated September 4, 2026, AbbVie closed its purchase of Apogee Therapeutics on September 3, 2026, paying USD 135.11 per Apogee share in cash for a total equity value of approximately USD 10.9 billion.

The deal brings Apogee's clinical-stage immunology pipeline into AbbVie, including candidates for atopic dermatitis, asthma and chronic obstructive pulmonary disease, complementing blockbuster drugs Skyrizi and Rinvoq that already anchor AbbVie's immunology franchise.

A separate US market wrap from HDFC Sky's US corporate summary notes that Apogee shareholders received USD 135.11 per share and that Apogee common stock ceased trading on Nasdaq before the market opened once the transaction closed.

Guidance and Q2 2026 figures support the equity story

Beyond the pipeline boost, the equity story remains anchored in AbbVie's current earnings power. As summarized by MarketBeat's guidance update dated September 3, 2026, AbbVie reaffirmed its adjusted EPS guidance for fiscal year 2026 at USD 13.87 to USD 14.07, broadly in line with the analyst consensus of about USD 14.02 per share.

For the third quarter of 2026, AbbVie guided to adjusted EPS between USD 3.84 and USD 3.88, which compares to second-quarter 2026 adjusted EPS of USD 3.65, a result that exceeded the USD 3.61 consensus by USD 0.04 per share.

In the same update, MarketBeat reports that AbbVie generated USD 16.99 billion in revenue in the second quarter of 2026, representing 10.2 percent year-over-year growth, a pace that reassures investors that the company is managing the Humira patent expiry whilst growing newer assets.

A deeper breakdown published on September 4, 2026 by 24/7 Wall St shows how the portfolio mix is shifting. In the second quarter of 2026, global Humira sales fell to USD 756 million, an operational decline of 36.1 percent versus the prior-year quarter, after a roughly 49.5 percent drop in fiscal 2025.

At the same time, Skyrizi delivered USD 5.5 billion in second-quarter 2026 sales at 24 percent year-over-year growth, while Rinvoq crossed USD 2.5 billion in quarterly revenue at 23.7 percent growth; neuroscience revenue topped USD 3.2 billion, underscoring how new growth engines are replacing declining Humira income.

The same analysis notes that total revenue in the quarter reached nearly USD 17.0 billion and that management raised full-year 2026 revenue guidance to approximately USD 67.6 billion, which investors can compare to the 10.2 percent growth rate to gauge how much further expansion is embedded in expectations.

For retail investors, the quantified contrast between Humira's 36.1 percent revenue decline in second-quarter 2026 and Skyrizi's 24 percent growth, coupled with Rinvoq's 23.7 percent increase, highlights the strategic pivot underway: earnings guidance stability in the USD 13.87 to USD 14.07 range depends increasingly on the durability of these newer immunology assets.

Dividend, free cash flow and consensus view

Income-focused shareholders are watching the dividend as closely as the pipeline. According to the same September 4, 2026 24/7 Wall St piece, AbbVie boosted its quarterly dividend by 5.5 percent to USD 1.73 per share, up from USD 1.64 previously, and maintained that rate for three consecutive payments.

The latest USD 1.73 quarterly dividend was paid on August 14, 2026, bringing the annualized dividend to about USD 6.92 per share, which is well covered by management's full-year 2026 adjusted EPS guidance midpoint of around USD 13.97.

24/7 Wall St further reports that AbbVie is generating about USD 17.8 billion in annual free cash flow, meaning that the dividend consumes only a portion of cash generation and leaving room for debt reduction after the USD 10.9 billion Apogee transaction.

Looking at the broader analyst picture, MarketBeat's guidance article notes that AbbVie carries a consensus rating of 'Moderate Buy' with an average price target of USD 275.95 per share for NYSE-listed AbbVie stock.

That average target of USD 275.95 stands roughly USD 15 above the recent trading region around USD 260, implying moderate upside potential in the eyes of covering analysts if the company hits the midpoint of its 2026 EPS guidance.

A separate comparative overview on MarketBeat's pharmaceutical stocks comparison page shows AbbVie with an annual dividend payout of USD 6.92 per share and a dividend yield of about 2.67 percent as of September 4, 2026, alongside a five-year annualized dividend growth rate of 6.80 percent.

For context, MarketBeat tables also show AbbVie shares around USD 261.37 in intraday trading on September 4, 2026, down 0.13 percent, with year-to-date performance of about 16.32 percent, positioning AbbVie as a solid performer within the large-cap pharmaceuticals peer group.

DACH investors and secondary trading access

For investors in the German-speaking DACH region, AbbVie is primarily accessible via its core listing on the New York Stock Exchange under the ticker ABBV, but it can also be traded on European platforms such as Tradegate, which offers secondary trading in US large-cap pharmaceutical names.

Sector comparison data from MarketBeat that includes Johnson and Johnson shares on Tradegate illustrates how dividend-focused investors in Europe often look at AbbVie alongside other global pharma dividend payers when they make allocation decisions, even though AbbVie itself is not a member of a DAX family index.

The combination of a nearly 2.7 percent dividend yield, a five-year annualized dividend growth rate of 6.80 percent and strong free cash flow makes AbbVie stock a relevant watchlist candidate for DACH investors seeking US healthcare exposure through their online brokers.

Skyrizi and Rinvoq as flagship products

Skyrizi and Rinvoq are central to AbbVie's attempt to reshape its revenue base after the Humira patent cliff. As outlined by 24/7 Wall St on September 4, 2026, Skyrizi generated USD 5.5 billion in revenue in the second quarter of 2026, growing 24 percent year over year, while Rinvoq delivered more than USD 2.5 billion and grew 23.7 percent.

Both medicines already treat multiple indications. MarketBeat's pharmaceutical comparison page describes Skyrizi as indicated for moderate to severe plaque psoriasis, psoriatic disease and Crohn's disease, while Rinvoq is approved for rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis and Crohn's disease.

The 24/7 Wall St analysis also points out that Skyrizi's composition-of-matter patent expires in 2033. AbbVie management highlighted later-expiring intellectual property in the mid-2030s and beyond and indicated that it does not expect biosimilar application filings for Skyrizi until the end of this decade.

For investors, these dates matter because they show that while Skyrizi and Rinvoq are driving current double-digit revenue growth, the company is already planning for a future period when biosimilar pressure might eventually affect these assets, much as it did Humira.

Stock level and investor perspective

Price data compiled by MarketBeat on September 4, 2026 shows AbbVie stock around USD 261.37 in intraday New York trading, down 0.13 percent on the day, with a 16.32 percent gain year to date and a 23.57 percent performance over the trailing twelve months.

That price sits modestly below the consensus analyst target of USD 275.95, and when combined with an annual dividend of USD 6.92 per share and a five-year annualized dividend growth rate of 6.80 percent, AbbVie offers a blend of income and moderate capital appreciation potential for long-term shareholders.

AbbVie Inc. fact box

• Company: AbbVie Inc.
• ISIN: US00287Y1091
• Ticker: ABBV
• Trading venue: NYSE
• Price (as of September 4, 2026): 261.37 USD
• Market capitalization: 435.00 billion USD (as of September 4, 2026)
• Sector / Industry: Pharmaceuticals / Biotechnology
• Index membership: S and P 500